Zhejiang Huakang Pharmaceutical Co., Ltd.

XSSC:605077 Stock Report

Market Cap: CN¥5.0b

Zhejiang Huakang Pharmaceutical Future Growth

Future criteria checks 2/6

Zhejiang Huakang Pharmaceutical is forecast to grow revenue at 28.2% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Food earnings growth22.1%
Revenue growth rate28.2%
Future return on equityn/a
Analyst coverage

Low

Last updated27 Sep 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

XSSC:605077 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20254,268N/AN/A5671
12/31/20243,589N/AN/A4291
9/30/20242,846284-1,151278N/A
6/30/20242,773325-1,021306N/A
3/31/20242,767361-602416N/A
12/31/20232,783371-71619N/A
9/30/20232,654339156661N/A
6/30/20232,61936318562N/A
3/31/20232,445359-133388N/A
12/31/20222,200319-268272N/A
9/30/20221,994308-345223N/A
6/30/20221,813263-191279N/A
3/31/20221,671236-219197N/A
12/31/20211,594237-97264N/A
9/30/20211,519257-121161N/A
6/30/20211,344237-127104N/A
3/31/20211,3112530257N/A
12/31/20201,32030782335N/A
9/30/20201,350297N/AN/AN/A
12/31/20191,511270149281N/A
12/31/20181,40019920141N/A
12/31/201792556N/A81N/A
12/31/201676329N/A93N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 605077's forecast earnings growth is above the savings rate (2.9%).

Earnings vs Market: Insufficient data to determine if 605077's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 605077's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 605077's revenue (28.2% per year) is forecast to grow faster than the CN market (14% per year).

High Growth Revenue: 605077's revenue (28.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 605077's Return on Equity is forecast to be high in 3 years time


Discover growth companies